Functional Uncoupling of T-cell Receptor Engagement and Lck Activation in Anergic Human Thymic CD4+ T Cells*

Wakae FujimakiDagger §, Makio Iwashima, Junji YagiDagger , Hua ZhangDagger , Hisako YagiDagger , Kazuhiro Seo||, Yasuharu Imai||, Ken'ichi ImanishiDagger , and Takehiko UchiyamaDagger

From the Dagger  Department of Microbiology and Immunology and || Department of Pediatric Cardiovascular Surgery, The Heart Institute of Japan, Tokyo Women's Medical University, Tokyo 162-8666, Japan and the  Program in Molecular Immunology, Institute of Molecular Medicine and Genetics, Medical College of Georgia, Augusta, Georgia 30912-2600

Received for publication, February 8, 2001


    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Human thymic CD1a-CD4+ T cells in the final stage of thymic maturation are susceptible to anergy induced by a superantigen, toxic shock syndrome toxin-1 (TSST-1). Thymic CD4+ T-cell blasts, established by stimulating human thymic CD1a-CD4+ T cells with TSST-1 in vitro, produce a low level of interleukin-2 after restimulation with TSST-1, whereas TSST-1-induced adult peripheral blood (APB) CD4+ T-cell blasts produce high levels of interleukin-2. The extent of tyrosine phosphorylation of the T-cell receptor zeta  chain induced after restimulation with TSST-1 was 2-4-fold higher in APB CD4+ T-cell blasts than in thymic CD4+ T-cell blasts. The tyrosine kinase activity of Lck was low in both thymic and APB CD4+ T-cell blasts before restimulation with TSST-1. After restimulation, the Lck kinase activity increased in APB CD4+ T-cell blasts but not in thymic CD4+ T-cell blasts. Surprisingly, Lck was highly tyrosine-phosphorylated in both thymic and APB CD4+ T-cell blasts before restimulation with TSST-1. After restimulation, it was markedly dephosphorylated in APB CD4+ T-cell blasts but not in thymic CD4+ T-cell blasts. Lck from APB CD4+ T-cell blasts bound the peptide containing the phosphotyrosine at the negative regulatory site of Lck-505 indicating that the site of dephosphorylation in TSST-1-activated T-cell blasts is Tyr-505. Confocal microscopy demonstrated that colocalization of Lck and CD45 was induced after restimulation with TSST-1 in APB CD4+ T-cell blasts but not in thymic CD4+ T-cell blasts. Further, remarkable accumulation of Lck in the membrane raft was observed in restimulated APB CD4+ T-cell blasts but not in thymic CD4+ T-cell blasts. These data indicate that interaction between Lck and CD45 is suppressed physically in thymic CD4+ T-cell blasts and plays a critical role in sustaining an anergic state.


    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Human thymic CD1a-CD4+ T cells in the final stage of maturation (1) and cord blood CD4+ T cells are susceptible to anergy induction by in vitro stimulation with a superantigen, toxic shock syndrome toxin-1 (TSST-1).1 Thymic and cord blood CD4+ T-cell blasts, prepared by stimulating human thymic CD1a-CD4+ and cord blood CD4+ T cells with TSST-1, exhibited low IL-2, IL-4, and interferon-gamma production and reduced proliferation after restimulation with TSST-1, whereas adult peripheral blood (APB) CD4+ T-cell blasts prepared in the same way exhibited high responses (2, 3). These characteristics indicate that cord blood and thymic CD4+ T cells are still functionally immature and that a post-thymic maturation process occurs in human peripheral blood T cells. To understand why these cells respond differently, it is essential to analyze the signal transduction pathway via T-cell receptor stimulation in anergic TSST-1-induced thymic CD4+ T-cell blasts.

Signal transduction via TCR stimulation involves at least two pathways: (i) activation of phospholipase C-gamma 1 and (ii) activation of the Ras-MAPK (mitogen-activated protein kinase) pathway. Both pathways require the activation of Src family kinases such as Lck and Fyn. Although mature T cells are highly resistant to anergy induction, they are rendered anergic when stimulated through TCR in the absence of costimulatory signals such as the CD28 molecule (4). Anergic T cells display various alterations in the two above mentioned pathways, including failure of ZAP-70, Ras, ERK (extracellular signal-related kinase), JNK (c-Jun NH2-terminal kinase), or AP-1 activation after restimulation with antigens (5-9). They also display constitutively elevated concentrations of intracellular free calcium and inositolphosphate, as well as increased tyrosine phosphorylation of phospholipase C-gamma 1, Fyn, and Cbl (10-12). It is not yet clear whether these defects are involved in the anergic state induced by TSST-1 in human thymic CD4+ T cells.

In the present study, we addressed the question of why human thymic CD1a-CD4+ T cells are induced into an anergic state after stimulation with TSST-1 by comparing signal transduction in anergic TSST-1-induced thymic CD4+ T-cell blasts with that in highly responsive TSST-1-induced APB CD4+ T-cell blasts. The results strongly suggest that the absence of an interaction between Lck and CD45 (which possesses phosphatase activity) is responsible for maintaining the anergic state of human thymic CD1a-CD4+ T cells induced by TSST-1.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Antibodies-- Antibodies (Abs) I2C3 (anti-HLA-DR/DP) and Nu Ts/c (anti-CD8) have been described previously (13). The following Abs were available commercially: a hybridoma cell line, OKT6 (anti-CD1a, American Type Culture Collection, Manassas, VA); FITC-conjugated SK3 (anti-CD4), phycoerythrin-conjugated SK1 (anti-CD8) and FITC- or phycoerythrin-conjugated SK7 (anti-CD3, Becton Dickinson, Mountain View, CA); RD-1 conjugated I2 (anti-DR, Coulter Immunology, Hialeah, FL); biotin-conjugated E22E7.2 (anti-Vbeta 2) and FITC-conjugated UCHL.1 (anti-CD45RO, Immunotech, Marseille, France); FITC-conjugated anti-CD28 (Immunotech, Marseille, France); FITC-conjugated avidin (Vector Laboratories, Burlingame, CA); 4G10 (anti-phosphotyrosine, Upstate Biotechnology Inc., Lake Placid, NY); 6B10.2 (anti-TCRzeta and anti-CD45 (M-20; Santa Cruz Biotechnology Inc., Santa Cruz, CA); and FITC-conjugated anti-CD45 and Texas red-conjugated avidin (PharMingen, San Diego, CA). The anti-Lck Ab was kindly provided by Dr. Y. Koga (Tokai University, Japan).

Preparation of APB CD4+ and Thymic CD1a-CD4+ T Cells-- The procedures used for preparing human lymphoid cells have been described previously (2). Briefly, APB mononuclear cells were isolated from the peripheral blood of healthy adult donors by Ficoll-Conray density gradient centrifugation. Whole APB T cells were obtained by the sheep red blood cell rosette method. After obtaining written informed consent, single-cell suspensions of thymocytes were obtained from thymus fragments dissected from donors, ranging in age from 3 to 24 years, during corrective cardiac surgery. To obtain APB CD4+ T cells, whole APB T cells were treated with Abs Nu Ts/c and I2C3. To obtain thymic CD1a-CD4+ T cells, thymocytes were first treated with peanut agglutinin, and then non-aggregated T cells were treated with a combination of Abs Nu Ts/c, I2C3, and OKT6. After washing, these Ab-treated cells were mixed with anti-mouse IgG coupled to magnetic beads (Dynabeads, Dynal, Oslo, Norway), and the mixtures were kept on ice for 30 min. Unbound cells were separated with a magnet and suspended in RPMI 1640 supplemented with 100 µg/ml streptomycin, 100 units/ml penicillin, 10% fetal calf serum, and 5 × 10-5 M 2-mercaptoethanol. The preparations of APB CD4+ and thymic CD1a-CD4+ T cells contained <5% CD8+ T cells, 5% CD8+ T cells, and 1% CD1a+ T cells, respectively.

Preparation of Antigen-presenting Cells-- DR+ L cells (8124) were used as antigen-presenting cells (APC). Before use as APC, DR+ L cells were irradiated at 30 gray with an x-ray irradiator and treated with 50 µg/ml mitomycin C for 30 min at 37 °C. APC were added to each well of microplates, 1 × 105 cells/well for 48-well plates or 1 × 106 cells/well for 6-well plates, and allowed to adhere overnight at 37 °C.

Preparation of TSST-1-induced APB and Thymic T-cell Blasts-- TSST-1-induced T-cell blasts were obtained as described previously (3). Briefly, APB CD4+ and thymic CD1a-CD4+ T cells were stimulated with 10 ng/ml TSST-1 (Toxin Technology, Inc., Sarasota, FL) on an APC monolayer for 3 days. Recovered cells were subjected to Percoll (density = 1.068) centrifugation. The large lymphoblasts obtained at the interface of the culture medium and Percoll were expanded by incubation with 100 units/ml recombinant IL-2 (Takeda Chemical Industries, Kyoto, Japan) for 4 days. Recovered cells were subjected to Percoll centrifugation. T-cell blasts were obtained at the interface between densities 1.050 and 1.068.

Assay for Production of IL-2-- For the assay of IL-2, T-cell blasts (5 × 105 cells/well) were stimulated with 10 ng/ml TSST-1 on an APC monolayer for various periods in 0.5-ml volumes in 48-well culture plates (Corning Glass). IL-2 activity in the culture supernatants was determined using IL-2-dependent CTLL-2 cells as reported previously (14). Data are presented as units/ml IL-2.

Flow Cytometric Analysis-- For expression of CD4 versus CD8, CD3 versus Vbeta 2, CD3 versus CD28, CD3 versus CD45RO, and CD3 versus HLA-DR in the T-cell preparations, T cells were stained with several combinations of the appropriate phycoerythrin-, RD1-, and FITC-conjugated Abs and examined by two-color flow cytometric analysis using an EPICS CS flow cytometer (Coulter Electronics, Hialeah, FL) as described previously (3). All procedures for cell staining were conducted on ice.

Immunoprecipitation and Immunoblotting-- T-cell blasts (2 × 107 cells/well) were restimulated with 2 µg/ml TSST-1 at 37 °C in 1-ml volumes in 6-well culture plates containing tightly adherent APC. At different time points, cultures were terminated by adding 5 ml of cold PBS, and T-cell blasts were collected immediately. After washing with cold PBS, the T-cell blasts were lysed in cold TNE buffer (containing 10 mM Tris-HCl (pH 7.4), 1% Nonidet P-40, 0.15 M NaCl, 1 mM EDTA, 1 mM Na3VO4, 10 µg/ml aprotinin and 300 µg/ml phenylmethylsulfonyl fluoride). Cell lysates were pre-cleared with Protein A/G Plus-agarose (Oncogene Science Inc., Uniondale, NY) and then incubated with Protein A/G Plus-agarose coupled to the respective antibody for 2 h at 4 °C. The immunoprecipitates were subjected to 10% SDS-polyacrylamide gel electrophoresis under reducing conditions, transferred to a polyvinylidene difluoride membrane, and immunoblotted with the indicated Ab followed by horseradish peroxidase-conjugated protein G (Zymed Laboratories Inc. Laboratories, San Francisco, CA) as the second Ab. The immunoblots were developed with the ECL system (Amersham Pharmacia Biotech, Buckinghamshire, UK).

In Vitro Kinase Assay-- T-cell blasts were solubilized in TNE buffer as described for immunoprecipitation, and the supernatants were subjected to immunoprecipitation for 2 h with an anti-Lck Ab. Immunoprecipitates were washed with radioimmune precipitation buffer (TNE buffer containing 0.1% sodium deoxycholate and 0.1% SDS) followed by washing buffer containing 20 mM Tris-HCl (pH 7.4) and 0.5 M LiCl. Immunoprecipitates were incubated with 30 µl of kinase reaction buffer containing 40 mM HEPES (pH 7.4), 3 mM MnCl2, 10% glycerol, 10 µM cold ATP, and 10 µCi of [gamma -32P]ATP (PerkinElmer Life Sciences) per sample. The reaction was allowed to proceed for 10 min at 30 °C; the samples were then centrifuged, and the supernatants were separated by reducing 8% SDS-polyacrylamide gel electrophoresis. After drying, the radioactivity bound to the gels was analyzed with a Molecular Imager System FX (Bio-Rad).

Precipitation of Tyrosine-phosphorylated Lck Carboxyl-terminal Peptide-- The sequence of a tyrosine-phosphorylated Lck carboxyl-terminal peptide (LckP peptide) containing the carboxyl-terminal 11 amino acids of Lck, Thr-Ala-Thr-Glu-Gly-Gln-Tyr-(PO3H2)-Gln-Pro-Gln-Pro, has been described by Sieh et al. (15). Biotin-conjugated LckP peptide was synthesized by BEX (Tokyo, Japan). Precipitation of LckP peptide was done as described previously (15). Briefly, cell lysates from T-cell blasts stimulated as described in immunoprecipitation were incubated with 50 µg/ml biotinylated LckP peptide for 2 h at 4 °C followed by incubation with streptavidin-conjugated agarose beads (Sigma) for 2 h. The precipitates were subjected to analysis by immunoblotting procedures as described above.

Immunofluorescence and Confocal Microscopy-- For immunofluorescence staining of CD45 and Lck, T-cell blasts were washed with PBS and fixed for 30 min in 3.7% paraformaldehyde in PBS at room temperature on glass slides pretreated with Cell-Tak (Collaborative Biomedical Products, Bedford, MA). Glass slides were then incubated with 0.1% Triton X-100 in PBS for 5 min to permeabilize the attached T-cell blasts and blocked for 15 min with 1% skimmed milk. The glass slides were incubated overnight at 4 °C with biotinylated anti-Lck Ab and FITC-conjugated anti-CD45 Ab at the appropriate concentrations followed by the incubation with Texas red-conjugated avidin as the second Ab overnight at 4 °C. After extensive washing with PBS, the glass slides were mounted using a glycerol solution containing anti-fade reagent (Molecular Probes, Eugene, OR).

Confocal imaging was performed with a laser head (MRC-600, Bio-Rad). Samples were excited at 488 and 568 nm, and fluorescein and Texas red signals were detected through the K2 and K1 filter blocks, respectively. Images were collected using the photon counting mode of the COMOS program (Bio-Rad). In double-labeling experiments, bleed-through of the Texas red signal into the fluorescein channel was negligible.

Sucrose Gradient Centrifugation-- To obtain the raft membrane fraction, T-cell blasts (7.5 × 107) were lysed with 1 ml of cold TNE buffer containing 10 mM Tris-HCl (pH 7.4), 1% TX-100, 0.15 M NaCl, 1 mM EDTA, 1 mM Na3VO4, 10 µg/ml aprotinin. The lysates were centrifuged for 5 min at 1300 × g to remove the nuclei and large cellular debris. For equilibrium centrifugation of the TX-100 lysates, the lysates was diluted with an equal volume of 80% w/v sucrose in TNE buffer. Then 0.8 ml of lysate-sucrose mixture was overlaid sequentially with 2 ml of 30% sucrose and 1 ml of 4% sucrose prepared in TNE, and the mixture was centrifuged at 200,000 × g for 16 h at 4 °C in an RPS 50-2 rotor (Hitachi, Tokyo, Japan). The gradient was fractionated into 0.5-ml fractions from the top of the tube. The raft and TX-100-soluble fractions were obtained in fractions 1-3 and 6-7, respectively.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

TSST-1-induced Human Thymic CD4+ T-cell Blasts Are in an Anergic State-- A summary of the surface phenotypes of TSST-1-induced thymic and APB CD4+ T-cell blasts used in this study is presented in Table I (under "Immunologic phenotypes"). Both type of cells show the phenotypes of TSST-1-reactive T cells. The percentage of TCR Vbeta 2+ T cells, which are the major TSST-1-reactive human T-cell fraction (16), was around 80% in both the thymic and APB T cell preparations. The intensity of TCR expression was equivalent in both preparations (data not shown). Most of the Vbeta 2-negative T cells among the thymic and APB T-cell blasts were likely to be other TSST-1-reactive fractions such as Vbeta 4+ T cells (17). The percentage of CD28+ T cells increased from around 70% before to around 90% after blast formation in both the thymic and APB T cell preparations, and the percentage of CD45RO+ T cells increased to a similar extent among both types of T-cell blasts. It should be noted that the percentage of HLA DR+ T cells was 3-fold lower among the thymic CD4+ T-cell blasts than among the APB CD4+ T-cell blasts. The APB and thymic CD4+ T-cell blasts were then restimulated with TSST-1 (10 ng/ml) on an APC monolayer and examined for IL-2 production (Table I, under "IL-2 production"). IL-2 production was much lower in the thymic CD4+ T-cell blasts than in the APB CD4+ T-cell blasts; the amount of IL-2 produced by the former was at most 10% of that produced by the latter. However, both the thymic and APB CD4+ T-cell blasts exhibited substantial IL-2 production upon stimulation with a combination of PMA and ionomycin (data not shown). These results indicate that thymic CD4+ T-cell blasts are in an anergic state following exposure to TSST-1.

                              
View this table:
[in this window]
[in a new window]
 
Table I
Immunologic phenotypes of thymic and APB CD4+ T cells before and after blast formation and TSST-1-induced IL-2 production of thymic and APB CD4+ T-cell blasts
Thymic and APB CD4+ T-cell blasts were prepared by stimulating thymic and APB CD4+ T cells with 10 ng/ml TSST-1 for 3 days on an APC monolayer and then expanding the large lymphoblasts with recombinant IL-2 for 4 days.

Reduced Tyrosine Phosphorylation of the TCRzeta Chain in Thymic CD4+ T-cell Blasts-- When T cells are activated by antigens, tyrosine phosphorylation of the TCRzeta chain is induced (18). The extent of tyrosine phosphorylation of the TCRzeta chain was therefore compared between TSST-1-induced thymic and APB CD4+ T-cell blasts. T-cell blasts were restimulated with TSST-1 (2 µg/ml) on an APC monolayer and cell lysates were prepared. The zeta  chain was immunoprecipitated and the extent of tyrosine phosphorylation was analyzed by Western blotting with an anti-phosphotyrosine Ab. As shown in the upper part of Fig. 1A, tyrosine phosphorylation of the zeta  chain was minimal in the absence of TSST-1 restimulation but showed significant increase after restimulation in both the thymic and APB T-cell blasts. The extent of phosphorylation was 2- to 4-fold higher in APB CD4+ T-cell blasts than in thymic CD4+ T-cell blasts. No difference in expression of the zeta  chain was detected between the two T-cell populations (lower part of Fig. 1A).


View larger version (28K):
[in this window]
[in a new window]
 
Fig. 1.   Lck in thymic CD4+ T-cell blasts is not functionally linked with TCR stimulation and stays constitutively tyrosine-phosphorylated at the negative regulator site Tyr-505. Thymic and APB CD4+ T-cell blasts were prepared as described in Table I and then restimulated with 2 µg/ml TSST-1 or unstimulated (Med) on an APC monolayer for the indicated times. A, the CD4+ T-cell blasts (1.2 × 107 cells/sample) were then lysed and immunoprecipitated (IP) with anti-TCRzeta Ab. The immunoprecipitates were blotted with anti-phosphotyrosine Ab (top panels) or anti-TCRzeta Ab (bottom panels). B, Lck was immunoprecipitated from the CD4+ T-cell blasts (2 × 107 cells/sample). The incorporated 32P count was compared between stimulated (TSST-1) and unstimulated (Med) samples, and the ratio of kinase activity presented is that from three independent autophosphorylation experiments. C, the CD4+ T-cell blasts (1.5 × 107 cells/sample) were lysed and immunoprecipitated with anti-Lck Ab. The immunoprecipitates were blotted with anti-phosphotyrosine Ab (upper panels) or anti-Lck Ab (lower panels). D, the CD4+ T-cell blasts (1.2 × 108 cells/sample) were lysed and mixed with the biotinylated LckP peptide. The peptide complex was precipitated with avidin-agarose beads. The precipitates and the total cell lysates were subjected to Western blot analysis with anti-Lck Ab.

Activation of Lck in Thymic CD4+ T-cell Blasts Is Impaired-- Because up-regulation of the tyrosine kinase activity of Lck plays a critical role in T-cell activation through TCR (19), the kinase activity of the Lck present in TSST-1-induced thymic and APB CD4+ T-cell blasts was studied next. Lck immunoprecipitates were prepared from restimulated T-cell blasts and were subjected to an in vitro kinase assay in which autophosphorylation of Lck was measured. In three independent experiments, a 2-14-fold increase in autophosphorylation was observed in the APB CD4+ T-cell blasts after restimulation with TSST-1 (Fig. 1B). In contrast, no elevation in autophosphorylation was observed in the thymic CD4+ T-cell blasts (Fig. 1B). These results indicate that the Lck kinase activity of APB CD4+ T-cell blasts increases markedly upon restimulation with TSST-1, whereas no such increase is induced in thymic CD4+ T-cell blasts.

Tyrosine kinase activity of src family kinases is regulated by phosphorylation and dephosphorylation of two tyrosine residues (Tyr-394 and Tyr-505 in Lck) (20-22). To determine why thymic CD4+ T-cell blasts restimulated with TSST-1 showed only weak Lck kinase activity, the extent of Lck tyrosine phosphorylation was compared in thymic and APB CD4+ T-cell blasts. Lck was immunoprecipitated from cell lysates of these T-cell blasts after restimulation with TSST-1 on an APC monolayer, and the extent of tyrosine phosphorylation was analyzed by Western blotting with an anti-phosphotyrosine Ab. Lck was highly tyrosine-phosphorylated in both thymic and APB CD4+ T-cell blasts when no restimulation was carried out. After restimulation, the extent of tyrosine phosphorylation was markedly reduced within 5 min in APB CD4+ T-cell blasts, whereas almost no change was observed in thymic CD4+ T-cell blasts (Fig. 1C, upper panels). Lck expression of was similar in both types of T-cell blasts (Fig. 1C, lower panels). Similar findings were observed 20 min after restimulation (data not shown).

Up-regulation of the Lck kinase activity is associated with phosphorylation of Tyr-394 (the autophosphorylation site) and dephosphorylation of the carboxyl-terminal tyrosine (Tyr-505) (20-22). The results shown in Fig. 1, B and C, suggests that TSST-1 restimulation induced dephosphorylation of phosphorylated Tyr-505 in APB CD4+ T-cell blasts but not in thymic CD4+ T-cell blasts. Phosphorylated Tyr-505 of Lck has been shown to bind to its own Src homology-2 domain, and it is postulated that this binding can cause the molecule to fold and thereby block kinase activity (23, 24). When phosphorylated Tyr-505 is dephosphorylated, Lck "opens out" and recovers the capacity to interact with a tyrosine-phosphorylated Lck carboxyl-terminal peptide (LckP peptide) (15).

To determine whether the Tyr-505 residue of Lck is the site at which dephosphorylation induced by restimulation with TSST-1 occurs in APB CD4+ T-cell blasts, binding of dephosphorylated Lck to LckP peptide was examined. Cell lysates prepared from T-cell blasts restimulated with TSST-1 on an APC monolayer were incubated with biotinylated LckP peptide. The precipitates were isolated with avidin-conjugated agarose beads and analyzed by Western blotting using an anti-Lck Ab. As shown in Fig. 1D (upper panels), the extent of precipitated Lck was minimal in the absence of TSST-1 restimulation, but restimulation in APB CD4+ T-cell blasts significantly increased the binding of Lck. In contrast, the LckP peptide-bound Lck did not increase after restimulation and rather showed a slight decrease in thymic CD4+ T-cell blasts. No difference in expression of the Lck was detected between the two T-cell populations (Fig. 1D, lower panels). These results show that the dephosphorylated Tyr-505 of Lck in TSST-1-induced APB CD4+ T-cell blasts is in the "open" configuration, whereas Lck of thymic blasts is in a "closed" form.

Lck and CD45 Are Physically Uncoulpled in Thymic CD4+ T-cell Blasts-- Because the Tyr-505 site of Lck is a potential substrate for the protein tyrosine phosphatase CD45 (25), CD45 may play a major role in the dephosphorylation of Lck in APB CD4+ T-cell blasts after restimlulation with TSST-1. To determine how Lck dephosphorylation is suppressed in thymic T-cell blasts, the subcellular localization of CD45 and Lck was determined by confocal microscopy. T-cell blasts restimulated with TSST-1 on an APC monolayer were separated from the monolayer and stained with FITC-conjugated anti-CD45 Ab and biotinylated anti-Lck Ab followed by Texas red-conjugated avidin. If Lck (red) and CD45 (green) were present in close proximity, the appearance of yellow dots would be observed. As shown in Fig. 2, Lck was expressed in both the membrane and cytoplamic areas of unstimulated thymic and APB CD4+ T-cell blasts, whereas CD45 was expressed mainly in the membrane. No colocalization of Lck and CD45 was observed in these cells. After restimulation with TSST-1, the intensity of the yellow color increased in the membrane of the APB CD4+ T-cell blasts, predominantly on one side of the blast, indicating that Lck and CD45 had become colocalized in the plasma membrane region after restimulation with TSST-1. In contrast, no colocalization of these two molecules was induced by restimulation of thymic CD4+ T-cell blasts. Although the distributions of Lck and CD45 are comparable with that of APB CD4+ T-cell blasts, double staining with anti-CD45 and anti-Lck clearly shows these molecules are present in discrete areas on the cell membrane.


View larger version (88K):
[in this window]
[in a new window]
 
Fig. 2.   Colocalization of CD45 and Lck is induced by TSST-1 stimulation on APB CD4+ T-cell blasts but not in thymic CD4+ T-cell blasts. Thymic and APB CD4+ T-cell blasts were prepared as described in Table I and then restimulated with 2 µg/ml TSST-1 or unstimulated (Medium) on an APC monolayer for 10 min. The T-cell blasts were fixed, permeabilized, and double-stained with anti-Lck Ab (red) and anti-CD45 Ab (green). The upper two rows show the fluorescence from each antibody, and the third row shows the combined fluorescence. Bright field pictures are shown in the bottom row.

Loss of Lck Localization into the Membrane Raft in Thymic T-cell Blasts-- Recent studies have shown that sphingolipid- and cholesterol-rich plasma membrane microdomains, termed membrane rafts, play an important role in TCR signal transduction. Raft aggregation promotes recruitment of signaling proteins such as Lck but excludes the tyrosine phosphatase CD45 (26, 27). Our data from confocal microscopy suggests that the physical interaction between CD45 and Lck in thymic T-cell blasts is much less than in APB T-cell blasts.

To test whether membrane rafts play a role in the process of Lck activation, we next determined the localization of Lck and CD45 inside and outside of the raft fraction. Cell lysates prepared from T-cell blasts restimulated with TSST-1 on an APC monolayer were lysed in a buffer containing nonionic detergent, and the lysates were fractionated by sucrose gradient centrifugation. As shown in Fig. 3A, Lck was mostly present outside of rafts in unstimulated T-cell blasts. After restimulation with TSST-1, a significant increase of Lck in rafts was observed in APB CD4+ T-cell blasts. In contrast, no increase of Lck in membrane rafts was induced by restimulation of thymic CD4+ T-cell blasts. This increase of Lck in the raft was more striking after a 70-min restimulation of APB T-cell blasts. Even at that point, no increase was observed in thymic T-cell blasts. Immunoprecipitation of Lck from the same fractionated lysates confirmed these results (Fig. 3A). In contrast to this accumulation of Lck in the raft, CD45 was present outside of the raft fraction throughout the restimulation in both types of T-cell blasts as previously reported (Fig. 3C).


View larger version (48K):
[in this window]
[in a new window]
 
Fig. 3.   Redistribution of Lck between inside and outside raft fraction is induced by TSST-1 stimulation on APB CD4+ T-cell blasts but not in thymic CD4+ T-cell blasts. Thymic and APB CD4+ T-cell blasts were prepared as described in Table I and then restimulated with 2 µg/ml TSST-1 or unstimulated (Medium) on an APC monolayer for indicated time. The CD4+ T-cell blasts (3 × 107 cells/sample) were then lysed in a buffer containing nonionic detergent, and the raft was fractionated by sucrose gradient centrifugation. The gradient was fractionated into 0.5-ml fractions from the top of the tube. A, each fraction was blotted with anti-Lck Ab. B, each fraction was immunoprecipitated with anti-Lck Ab. The precipitates were blotted with anti-Lck Ab. C, each fraction was blotted with anti-CD45 Ab.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Human thymic CD1a-CD4+ T cells are highly susceptible to anergy induction by superantigens, whereas APB CD4+ T cells are resistant, as shown in a previous study (2) and in Table I. T cells are rendered anergic when they are stimulated through TCR in the absence of costimulatory signals such as the CD28 molecule (4). However, the absence of a costimulatory signal is not responsible for the high susceptibility of thymic CD1a-CD4+ T cells to TSST-1-induced anergy, because the percentage of CD28+ T cells among unstimulated thymic and APB CD4+ T cells was similar. We did not find any differences in surface phenotypes to explain the differences in susceptibility to anergy induction between unstimulated thymic and APB CD4+ T cells (Table I). In the present study, we examined signal transduction in thymic and APB CD4+ T-cell blasts before and after restimulation with TSST-1. The results strongly suggest the presence of a novel regulatory mechanism that controls an interaction between Lck and CD45.

The activity of CD45 is regulated by several mechanisms including isoform specific regulation (28). In this study, the level of CD45RO expression was similar in both thymic and APB CD4+ T-cell blasts (Table I), ruling out the possibility that isoform differences caused the impairment of CD45 function in thymic CD4+ T-cell blasts. Instead, our results show a remarkable difference in the physical localization of CD45 and Lck after restimulation with TSST-1 in thymic CD4+ T-cell blasts. An analysis of the subcellular localization of CD45 and Lck in thymic and APB CD4+ T-cell blasts after restimulation with TSST-1 showed that Lck and CD45 were physically associated in the membrane region of APB CD4+ T-cell blasts but not thymic CD4+ T-cell blasts (Fig. 2).

Membrane-associated molecules are known to localize to a specifically designated area composed of discrete lipid microdomains (26, 27). Some but not all of the Lck localizes in sphingolipid-cholesterol rafts, whereas no association of CD45 with these rafts has been observed (27, 29). Several studies have shown that a synaptic structure is formed by dynamic relocalization of various molecules at the site of the interaction between T cells and APC (30-32). The central zone of the synaptic structure formed between T cells and APC is rich in TCR, CD4, and CD28, whereas CD45 remains on the outside (31, 32). This discrete localization of CD45 and Lck indicates that there is a dynamic process involved in the interaction between these two molecules. A potential model is that repartitioning of Lck from the outside to the inside of sphingolipid-cholesterol rafts is regulated by interaction with CD45. In this view, Lck, which resided outside of the raft, gets dephosphorylated after stimulation and localizes in the raft. With thymic T-cell blasts, the interaction between CD45 and Lck is blocked, and thus this translocation into the raft is blocked (Fig. 4, MODEL 1). Alternatively, although CD45 is not within the raft, it only interacts with Lck within the raft. In thymic T-cell blasts, Lck localization into rafts is blocked, and as a result, its interaction with CD45 is impaired (Fig. 4, MODEL 2). We are currently testing these hypotheses.


View larger version (32K):
[in this window]
[in a new window]
 
Fig. 4.   Models for the regulatory mechanism of the Lck activity: interaction with CD45 and localization to the raft. Model 1 predicts that Lck interacts with CD45 prior to accumulation in the raft, whereas model 2 predicts that Lck interacts with CD45 after it localizes within the raft. The data presented here shows that interaction between CD45 and Lck is suppressed. This inhibition could take place outside (MODEL 1) or inside (MODEL 2) of the raft. In both cases, dephosphorylated Lck (Lck*) accumulates within the raft.

Taken together, these results suggest the presence of a novel regulatory mechanism that controls localization of CD45 and Lck in activated T cells. Most importantly, this regulation may play a critical role in the maintenance of the anergic state of human thymic CD1a-CD4+ T cells induced by superantigens.

    ACKNOWLEDGEMENTS

We are grateful to Dr. Takamitsu Fujimaki (University of Teikyo, Japan) for helpful discussion during the experiments, Dr. Pandlakis Koni (Medical College of Georgia) for critical reading of the manuscript, and to Dr. Yasuhiro Koga (Tokai University, Kanagawa, Japan) for providing the anti-Lck antibody.

    FOOTNOTES

* This work was supported in part by Grants-in-aid 08670320 and 11670276 from the Ministry of Education, Science, Culture and Sports of Japan and by a grant from the Itoe Okamoto Foundation.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§ To whom correspondence should be addressed: Dept. of Microbiology and Immunology, Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo 162-8666, Japan. Tel.: 81-3-3353-8111; Fax: 81-3-5269-7411; E-mail: wakae@research.twmu.ac.jp.

Published, JBC Papers in Press, February 22, 2001, DOI 10.1074/jbc.M101072200

    ABBREVIATIONS

The abbreviations used are: TSST-1, toxic shock syndrome toxin-1; IL, interleukin; APB, adult peripheral blood; TCR, T-cell receptor; Ab, antibody; FITC, fluorescein isothiocyanate; APC, antigen-presenting cell; PBS, phosphate-buffered saline.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Res, P., Blom, B., Hori, T., Weijer, K., and Spits, H. (1997) J. Exp. Med. 185, 141-151[Abstract/Free Full Text]
2. Imanishi, K., Seo, K., Kato, H., Miyoshi-Akiyama, T., Zhang, R. H., Takahashi, Y., Imai, Y., and Uchiyama, T. (1998) J. Immunol. 160, 112-119[Abstract/Free Full Text]
3. Takahashi, N., Imanishi, K., Nishida, H., and Uchiyama, T. (1995) J. Immunol. 155, 5213-5219[Abstract]
4. Mueller, D. L., Jenkins, M. K., and Shwartz, R. H. (1989) J. Immunol. 142, 2617-2627[Abstract/Free Full Text]
5. Migita, K., Eguchi, K., Kawabe, Y., Tsukada, T., Ichinose, Y., and Nagataki, S. (1995) J. Immunol. 155, 5083-5087[Abstract]
6. Li, W., Whaley, C. D., Mondio, A., and Muller, D. L. (1996) Science 271, 1272-1276[Abstract]
7. Fields, P. E., Gajewski, T. F., and Fitch, F. W. (1996) Science 271, 1276-1278[Abstract]
8. DeSilva, D. R., Feeser, W. S., Tancula, E. J., and Scherle, P. A. (1996) J. Exp. Med. 183, 2017-2023[Abstract]
9. Kang, S. M., Beverly, B., Tran, A. C., Brorson, K., Shwartz, R. H., and Lenardo, M. J. (1992) Science 257, 1134-1138[Medline] [Order article via Infotrieve]
10. Gajewski, T. F., Qian, D., Fields, P., and Fitch, F. W. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 38-42[Abstract]
11. Boussiotis, V. A., Freeman, G. J., Berezovskaya, A., Barber, D. L., and Nadler, L. M. (1997) Science 278, 124-128[Abstract/Free Full Text]
12. Gajewski, T. F., Fields, P., and Fitch, F. W. (1995) Eur. J. Immunol. 25, 1836-1842[Medline] [Order article via Infotrieve]
13. Akatsuka, H., Imanishi, K., Inada, K., Yamashita, H., Yoshida, M., and Uchiyama, T. (1994) Clin. Exp. Immunol. 96, 422-426[Medline] [Order article via Infotrieve]
14. Uchiyama, T., Kamagata, Y., Yan, X-J., Kohno, M., Yoshioka, M., Fujikawa, H., Igarashi, H., Okubo, M., Awano, F., Saito-Taki, T., and Nakano, M. (1987) Clin. Exp. Immunol. 68, 638-647[Medline] [Order article via Infotrieve]
15. Sieh, M., Bolen, J. B., and Weiss, A. (1993) EMBO J. 12, 315-321[Abstract]
16. Choi, Y., Kotzin, B, Herron, L., Callahan, J., and Marrack, P. (1989) Proc. Natl. Acad. Sci. U. S. A. 86, 8941-8945[Abstract]
17. Kato, H., Fujimaki, W., Narimatsu, H., Yagi, J., Imanishi, K., and Uchiyama, T. (1994) J. Tokyo Womens Med. College 64, 985-993
18. Weiss, A. (1993) Cell 73, 209-212[Medline] [Order article via Infotrieve]
19. Straus, D. B., and Weiss, A. (1992) Cell 70, 585-593[Medline] [Order article via Infotrieve]
20. Amrein, KE., and Sefton, B. M. (1988) Proc. Natl. Acad. Sci. U. S. A. 85, 4247-4251[Abstract]
21. Marth, J. D., Cooper, J. A., King, C. S., Ziegler, S. F., Tinker, D. A., Overell, R. W., Krebs, E. G., and Perlmutter, R. M. (1988) Mol. Cell. Biol. 8, 540-550[Medline] [Order article via Infotrieve]
22. Veillette, A., and Fournel, M. (1990) Oncogene 5, 1455-1462[Medline] [Order article via Infotrieve]
23. Cantley, L. C., Auger, K. R., Carpenter, C., Duckworth, B., Grazini, A., Kapeller, R., and Soltoff, S. (1991) Cell 64, 281-302[Medline] [Order article via Infotrieve]
24. Koch, C. A., Anderson, D., Moran, M. F., Ellis, C., and Pawson, T. (1991) Science 252, 668-674[Medline] [Order article via Infotrieve]
25. Mustelin, T., Coggeshal, K. M., and Altman, A. (1989) Proc. Natl. Acad. Sci. U. S. A. 86, 6302-6306[Abstract]
26. Simons, K., and Ikonen, E. (1997) Nature 387, 569-572[CrossRef][Medline] [Order article via Infotrieve]
27. Zhang, W., Trible, R. P., and Samelson, L. E. (1998) Immunity 9, 239-246[Medline] [Order article via Infotrieve]
28. Leitenberg, D., Boutin, Y., Lu, D. D., and Bottomly, K. (1999) Immunity 10, 701-711[Medline] [Order article via Infotrieve]
29. Rodgers, W., and Rose, J. K. (1996) J. Cell Biol. 135, 1515-1523[Abstract]
30. Viola, A., Schroeder, S., Sakakibara, Y., and Lanzavecchia, A. (1999) Science 283, 680-682[Abstract/Free Full Text]
31. Grakoui, A., Bromley, S. K., Sumen, C., Davis, M. M., Shaw, A. S., Allen, P. M., and Dustin, M. L. (1999) Science 285, 221-227[Abstract/Free Full Text]
32. Monks, C. R. F., Freiberg, B. A., Kupfer, H., Sciaky, N., and Kupfer, A. (1998) Nature 395, 82-86[CrossRef][Medline] [Order article via Infotrieve]


Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.